Clinical efficacy and safety of paclitaxel liposomes as first-line chemotherapy in advanced gastric cancer
To compare the performance of first-line paclitaxel liposome + oxaliplatin and SOX (tegafur/gimeracil/oteracil + oxaliplatin) in advanced gastric cancer patients. Stage IIb–IV gastric cancer patients underwent either first-line paclitaxel liposome + oxaliplatin (n = 52) or SOX (n = 69) between 201...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2019-05, Vol.15 (14), p.1617-1627 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1627 |
|---|---|
| container_issue | 14 |
| container_start_page | 1617 |
| container_title | Future oncology (London, England) |
| container_volume | 15 |
| creator | Han, Guangjie Shi, Jianfei Mi, Lili Li, Ning Shi, Huacun Li, Cuizhen Shan, Baoen Yin, Fei |
| description | To compare the performance of first-line paclitaxel liposome + oxaliplatin and SOX (tegafur/gimeracil/oteracil + oxaliplatin) in advanced gastric cancer patients.
Stage IIb–IV gastric cancer patients underwent either first-line paclitaxel liposome + oxaliplatin (n = 52) or SOX (n = 69) between 2010–2013, and followed up until 2015 or death.
Both groups had similar objective response rate (p = 0.48) and disease control rate (p = 0.992) after two chemotherapy cycles, median progression-free survival (p = 0.495) and median overall survival (p = 0.208). Liposome group had significantly lower rate of grade I–II platelet decline and liver function damage (p = 0.04 and 0.019). Multivariate COX regression identified pre-treatment neutrophil-to-lymphocyte ratio as an independent prognostic factor.
First-line paclitaxel liposome + oxaliplatin has comparable efficacy, but causes reduced adverse reactions in advanced gastric cancer as compared with SOX. |
| doi_str_mv | 10.2217/fon-2018-0439 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2217477292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2217477292</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-8d0979676e814021bc57785c2d6a4eab184736fbb0cf17c5fc81b667262902873</originalsourceid><addsrcrecordid>eNp1kc1v1DAQxS0Eou22R67IEhcuBn-t7RzRio9KlXop58iZjKlXSRzsBLH_PQ5bOCBxmhnpN08z7xHySvB3Ugr7PqSJSS4c41o1z8ilsFozp7h4XnttG2ZMoy_IVSlHzrVVe_6SXCjBlVNGXZLjYYhTBD9QDKFWOFE_9bT4gMuJpkBnD0Nc_E8c6BDnVNKIhfpCQ8xlYXUZKTzimJZHzH4-0ThR3__wE2BPv_my5AgUtjFfkxfBDwVvnuqOfP308eHwhd3df749fLhjoJVdmOt5YxtjDTqhuRQd7K11e5C98Rp9J1z9woSu4xCEhX0AJzpjrDSy4dJZtSNvz7pzTt9XLEs7xgI4DH7CtJZ2s01bKxtZ0Tf_oMe05qleVymrKrj5tCPsTEFOpWQM7Zzj6POpFfy3WltDaLcQ2i2Eyr9-Ul27Efu_9B_XK9CcgbAua8YCEatB7XmqGxGqrf8R_wW1jZWi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2273217038</pqid></control><display><type>article</type><title>Clinical efficacy and safety of paclitaxel liposomes as first-line chemotherapy in advanced gastric cancer</title><source>PubMed Central</source><creator>Han, Guangjie ; Shi, Jianfei ; Mi, Lili ; Li, Ning ; Shi, Huacun ; Li, Cuizhen ; Shan, Baoen ; Yin, Fei</creator><creatorcontrib>Han, Guangjie ; Shi, Jianfei ; Mi, Lili ; Li, Ning ; Shi, Huacun ; Li, Cuizhen ; Shan, Baoen ; Yin, Fei</creatorcontrib><description>To compare the performance of first-line paclitaxel liposome + oxaliplatin and SOX (tegafur/gimeracil/oteracil + oxaliplatin) in advanced gastric cancer patients.
Stage IIb–IV gastric cancer patients underwent either first-line paclitaxel liposome + oxaliplatin (n = 52) or SOX (n = 69) between 2010–2013, and followed up until 2015 or death.
Both groups had similar objective response rate (p = 0.48) and disease control rate (p = 0.992) after two chemotherapy cycles, median progression-free survival (p = 0.495) and median overall survival (p = 0.208). Liposome group had significantly lower rate of grade I–II platelet decline and liver function damage (p = 0.04 and 0.019). Multivariate COX regression identified pre-treatment neutrophil-to-lymphocyte ratio as an independent prognostic factor.
First-line paclitaxel liposome + oxaliplatin has comparable efficacy, but causes reduced adverse reactions in advanced gastric cancer as compared with SOX.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2018-0439</identifier><identifier>PMID: 31038363</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>advanced gastric cancer ; adverse reactions ; Cancer therapies ; Cell division ; Chemotherapy ; Committees ; Gastric cancer ; Lymphocytes ; Medical prognosis ; Neutrophils ; NLR ; paclitaxel liposomes ; Patients ; prognosis ; SOX ; Surgery ; Tumors</subject><ispartof>Future oncology (London, England), 2019-05, Vol.15 (14), p.1617-1627</ispartof><rights>2019 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd May 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-8d0979676e814021bc57785c2d6a4eab184736fbb0cf17c5fc81b667262902873</citedby><cites>FETCH-LOGICAL-c437t-8d0979676e814021bc57785c2d6a4eab184736fbb0cf17c5fc81b667262902873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31038363$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Han, Guangjie</creatorcontrib><creatorcontrib>Shi, Jianfei</creatorcontrib><creatorcontrib>Mi, Lili</creatorcontrib><creatorcontrib>Li, Ning</creatorcontrib><creatorcontrib>Shi, Huacun</creatorcontrib><creatorcontrib>Li, Cuizhen</creatorcontrib><creatorcontrib>Shan, Baoen</creatorcontrib><creatorcontrib>Yin, Fei</creatorcontrib><title>Clinical efficacy and safety of paclitaxel liposomes as first-line chemotherapy in advanced gastric cancer</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>To compare the performance of first-line paclitaxel liposome + oxaliplatin and SOX (tegafur/gimeracil/oteracil + oxaliplatin) in advanced gastric cancer patients.
Stage IIb–IV gastric cancer patients underwent either first-line paclitaxel liposome + oxaliplatin (n = 52) or SOX (n = 69) between 2010–2013, and followed up until 2015 or death.
Both groups had similar objective response rate (p = 0.48) and disease control rate (p = 0.992) after two chemotherapy cycles, median progression-free survival (p = 0.495) and median overall survival (p = 0.208). Liposome group had significantly lower rate of grade I–II platelet decline and liver function damage (p = 0.04 and 0.019). Multivariate COX regression identified pre-treatment neutrophil-to-lymphocyte ratio as an independent prognostic factor.
First-line paclitaxel liposome + oxaliplatin has comparable efficacy, but causes reduced adverse reactions in advanced gastric cancer as compared with SOX.</description><subject>advanced gastric cancer</subject><subject>adverse reactions</subject><subject>Cancer therapies</subject><subject>Cell division</subject><subject>Chemotherapy</subject><subject>Committees</subject><subject>Gastric cancer</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Neutrophils</subject><subject>NLR</subject><subject>paclitaxel liposomes</subject><subject>Patients</subject><subject>prognosis</subject><subject>SOX</subject><subject>Surgery</subject><subject>Tumors</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc1v1DAQxS0Eou22R67IEhcuBn-t7RzRio9KlXop58iZjKlXSRzsBLH_PQ5bOCBxmhnpN08z7xHySvB3Ugr7PqSJSS4c41o1z8ilsFozp7h4XnttG2ZMoy_IVSlHzrVVe_6SXCjBlVNGXZLjYYhTBD9QDKFWOFE_9bT4gMuJpkBnD0Nc_E8c6BDnVNKIhfpCQ8xlYXUZKTzimJZHzH4-0ThR3__wE2BPv_my5AgUtjFfkxfBDwVvnuqOfP308eHwhd3df749fLhjoJVdmOt5YxtjDTqhuRQd7K11e5C98Rp9J1z9woSu4xCEhX0AJzpjrDSy4dJZtSNvz7pzTt9XLEs7xgI4DH7CtJZ2s01bKxtZ0Tf_oMe05qleVymrKrj5tCPsTEFOpWQM7Zzj6POpFfy3WltDaLcQ2i2Eyr9-Ul27Efu_9B_XK9CcgbAua8YCEatB7XmqGxGqrf8R_wW1jZWi</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Han, Guangjie</creator><creator>Shi, Jianfei</creator><creator>Mi, Lili</creator><creator>Li, Ning</creator><creator>Shi, Huacun</creator><creator>Li, Cuizhen</creator><creator>Shan, Baoen</creator><creator>Yin, Fei</creator><general>Future Medicine Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190501</creationdate><title>Clinical efficacy and safety of paclitaxel liposomes as first-line chemotherapy in advanced gastric cancer</title><author>Han, Guangjie ; Shi, Jianfei ; Mi, Lili ; Li, Ning ; Shi, Huacun ; Li, Cuizhen ; Shan, Baoen ; Yin, Fei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-8d0979676e814021bc57785c2d6a4eab184736fbb0cf17c5fc81b667262902873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>advanced gastric cancer</topic><topic>adverse reactions</topic><topic>Cancer therapies</topic><topic>Cell division</topic><topic>Chemotherapy</topic><topic>Committees</topic><topic>Gastric cancer</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Neutrophils</topic><topic>NLR</topic><topic>paclitaxel liposomes</topic><topic>Patients</topic><topic>prognosis</topic><topic>SOX</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Han, Guangjie</creatorcontrib><creatorcontrib>Shi, Jianfei</creatorcontrib><creatorcontrib>Mi, Lili</creatorcontrib><creatorcontrib>Li, Ning</creatorcontrib><creatorcontrib>Shi, Huacun</creatorcontrib><creatorcontrib>Li, Cuizhen</creatorcontrib><creatorcontrib>Shan, Baoen</creatorcontrib><creatorcontrib>Yin, Fei</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Han, Guangjie</au><au>Shi, Jianfei</au><au>Mi, Lili</au><au>Li, Ning</au><au>Shi, Huacun</au><au>Li, Cuizhen</au><au>Shan, Baoen</au><au>Yin, Fei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical efficacy and safety of paclitaxel liposomes as first-line chemotherapy in advanced gastric cancer</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>15</volume><issue>14</issue><spage>1617</spage><epage>1627</epage><pages>1617-1627</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>To compare the performance of first-line paclitaxel liposome + oxaliplatin and SOX (tegafur/gimeracil/oteracil + oxaliplatin) in advanced gastric cancer patients.
Stage IIb–IV gastric cancer patients underwent either first-line paclitaxel liposome + oxaliplatin (n = 52) or SOX (n = 69) between 2010–2013, and followed up until 2015 or death.
Both groups had similar objective response rate (p = 0.48) and disease control rate (p = 0.992) after two chemotherapy cycles, median progression-free survival (p = 0.495) and median overall survival (p = 0.208). Liposome group had significantly lower rate of grade I–II platelet decline and liver function damage (p = 0.04 and 0.019). Multivariate COX regression identified pre-treatment neutrophil-to-lymphocyte ratio as an independent prognostic factor.
First-line paclitaxel liposome + oxaliplatin has comparable efficacy, but causes reduced adverse reactions in advanced gastric cancer as compared with SOX.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>31038363</pmid><doi>10.2217/fon-2018-0439</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2019-05, Vol.15 (14), p.1617-1627 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2217477292 |
| source | PubMed Central |
| subjects | advanced gastric cancer adverse reactions Cancer therapies Cell division Chemotherapy Committees Gastric cancer Lymphocytes Medical prognosis Neutrophils NLR paclitaxel liposomes Patients prognosis SOX Surgery Tumors |
| title | Clinical efficacy and safety of paclitaxel liposomes as first-line chemotherapy in advanced gastric cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T05%3A38%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20efficacy%20and%20safety%20of%20paclitaxel%20liposomes%20as%20first-line%20chemotherapy%20in%20advanced%20gastric%20cancer&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Han,%20Guangjie&rft.date=2019-05-01&rft.volume=15&rft.issue=14&rft.spage=1617&rft.epage=1627&rft.pages=1617-1627&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2018-0439&rft_dat=%3Cproquest_cross%3E2217477292%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2273217038&rft_id=info:pmid/31038363&rfr_iscdi=true |